MedPath

Otsuka Novel Products GmbH

Otsuka Novel Products GmbH logo
🇩🇪Germany
Ownership
Subsidiary
Established
2005-01-01
Employees
-
Market Cap
-
Website
http://www.otsuka-onpg.com

Clinical Trials

2

Active:1
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

3

EMA:2
CIMA_AEMPS:1

Drug Approvals

Deltyba

Authorization Status
Authorised
Approval Date
Apr 27, 2014
EMA

Deltyba

Authorization Status
Authorised
Approval Date
Apr 27, 2014
EMA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

Phase 1
Terminated
Conditions
Breast Cancer
Ovarian Cancer
Prostate Cancer
Salivary Gland Cancer
Endometrial Cancer
Squamous Cell Carcinoma of the Cervix
Interventions
First Posted Date
2014-01-23
Last Posted Date
2015-10-20
Lead Sponsor
Otsuka Novel Products GmbH
Target Recruit Count
79
Registration Number
NCT02042885
Locations
🇬🇧

The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, Sutton, Surrey, United Kingdom

🇬🇧

NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital, London, United Kingdom

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.